- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01054976
The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease
November 23, 2012 updated by: Janssen Korea, Ltd., Korea
This study will examine whether the administration of galantamine is effective for improvement of attention and more effective for patients with serious disturbance of attention by administering galantamine to patients with Alzheimer's dementia and performing an attention test on baseline, week 4 and 12.
Study Overview
Detailed Description
This is an open label (all people know the identity of the intervention), multi-center, prospective study investigating the effect of galantamine on the attention of Alzheimer's dementia patients.
The objectives of this study include the evaluation of the relationship between change in attention after 4 weeks of galantamine administration and to investigate the effect of study drug after 12 weeks administration (the difference in the improvement of attention after the administration of galantamine).
The secondary objective of this study is to clarify the causal relationship between improvement of attention and activities of daily living (ADL).
The design of this study is prospective, open-label, multi-center study.
Study populations are probable Alzheimer's dementia patients diagnosed by NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's disease and Related Disorders Association), DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria.
The efficacy of study drug will be assessed by evaluating cognitive function, attention and behavioral symptoms before and after the treatment using the following assessment tools: ADAS-K-cog11 (Alzheimer's Disease Assessment Scale - cognitive subscale), computerized attention test and activities of daily living.
Safety evaluations include adverse event monitoring and clinical lab tests.
The patient is administered oral galantamine 8 mg/day for the first 4 weeks and then 16 mg/day.
The dose of galantamine is increased up to 24 mg if tolerated.
Study Type
Interventional
Enrollment (Actual)
99
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Alzheimer's disease according to the criteria of DSM-IV, NINCDS-ADRDA
- K-MMSE (Korean - Mini Mental State Exam) is 10 to 24
- Reliable Guardian available to the patients
- Patient or guardian provided written informed consent before entering into the clinical trial
Exclusion Criteria:
- Acetylcholine esterase inhibitors used to treat dementia taken within 30 days of the beginning in this clinical trial
- Neurodegenerative diseases (eg Parkinson's disease, Pick's disease, Huntington's disease, Down syndrome)
- Dementia related to head trauma and dementia related to brain damage due to cerebral hypoxia (hypoxic brain damage after cardiopulmonary resuscitation, hypoxic brain damage after surgery, hypoxic brain damage due to addiction, hypoxic brain damage due to shock)
- brain tumor, nerve syphilis, meningitis, encephalitis
- epilepsy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Galantamine
|
Orally administered Galantamine 8 mg/day for the first 4 weeks.
Thereafter the dose will be increased to 16 mg/day.
If tolerated, the dose of galantamine can be increased up to 24 mg/day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Simple Reaction Time
Time Frame: Baseline, Week 12
|
The Simple Reaction Time is a computerized attention test that evaluates the patient's reaction time when the color of the computer screen changes from black to white by performing a total of 70 times for six minutes.
|
Baseline, Week 12
|
Change From Baseline in Choice Reaction Time
Time Frame: Baseline, Week 12
|
The Choice Reaction Time is a computerized attention test that evaluates the reaction time and the number of errors by showing patients one card on the computer screen and making them find the same one among similar four cards.
The test is performed a total of 12 times.
|
Baseline, Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
Time Frame: Baseline, Week 12
|
The Alzheimer's disease Assessment Scale-Cognitive subscale (ADAS-Cog) is an instrument used to assess cognitive dysfunction in individuals with Alzheimer disease and other dementias.
It consists of 11 items, with scores ranging from 1 to 70.
Maximum score is 70.
Higher scores indicate worsening.
|
Baseline, Week 12
|
Change From Baseline in Korean Version of Disability Assessment for Demential Scale (DAD-K)
Time Frame: Baseline, Week 12
|
DAD-K is the Korean version of the Assessment for Dementia Scale, a tool developed to evaluate the Alzheimer patients' function including both basic and instrumental Activities of Daily Livings (ADL).
It evaluates one function from various perspectives including behavior initiation, plan and preparation, and valid performance.
It consists of 10 questions, each can score either 0 (no) or 1 (yes), if not applicable, patient will check on "not applicable (x)" which will not count in the calculation.
Scores range from 0 to 100.
Higher score represents better function
|
Baseline, Week 12
|
Change From Baseline in Seoul-Instrumental Activities of Daily Livings (S-IADL)
Time Frame: Baseline, Week 12
|
The Seoul-Instrumental Activities of Daily Living (S-IADL) assesses patients' abilities to perform instrumental and social activities of daily living.
These include the ability to prepare a balanced meal, remember appointments, keep financial records, remember to take medication, and so on.
It is composed of 15 items, with scores ranging from 0 to 45. Lower scores indicate better functioning.
|
Baseline, Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Primary Completion (Actual)
February 1, 2009
Study Completion (Actual)
February 1, 2009
Study Registration Dates
First Submitted
January 21, 2010
First Submitted That Met QC Criteria
January 21, 2010
First Posted (Estimate)
January 22, 2010
Study Record Updates
Last Update Posted (Estimate)
December 24, 2012
Last Update Submitted That Met QC Criteria
November 23, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Alzheimer Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Parasympathomimetics
- Galantamine
Other Study ID Numbers
- CR015850
- GAL-KOR-21 (Other Identifier: Janssen Korea, Ltd., Korea)
- GALALZ4039 (Other Identifier: Janssen Korea, Ltd., Korea)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on Galantamine
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Samsung Medical CenterJanssen Korea, Ltd., KoreaCompleted
-
Ludwig-Maximilians - University of MunichUnknownAlzheimer's DiseaseGermany
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH); Massachusetts General HospitalCompletedBipolar DisorderUnited States
-
The University of Texas Health Science Center,...Completed
-
Janssen Pharmaceutical K.K.CompletedAlzheimer's DiseaseJapan
-
Actavis Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedAlzheimer Disease
-
Actavis Inc.Completed